At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Closed 12-05 16:00:00 EST
2.06
-0.08
-3.74%
盘后2.10
+0.04+1.94%
19:58 EST
High2.17Low1.99Vol215.65K
Open2.03D1 Closing2.14Amplitude8.41%
Mkt Cap6.73MTradable Cap5.14MTotal Shares3.27M
T/O448.96KT/O Rate8.64%Tradable Shares2.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Gri Bio Faces Nasdaq Delisting Threat Over Equity Rule Violation
Reuters  ·  12-02
Gri Bio Faces Nasdaq Delisting Threat Over Equity Rule Violation
China's First Specialized Policy on Green Trade Unveiled, Marking a New Phase of Systematic Advancement
Deep News  ·  11-19
China's First Specialized Policy on Green Trade Unveiled, Marking a New Phase of Systematic Advancement
Lv Jianzhong: Enterprises Should Seize Green Trade Policy Opportunities in Three Key Areas
Deep News  ·  11-17
Lv Jianzhong: Enterprises Should Seize Green Trade Policy Opportunities in Three Key Areas
China's First Specialized Policy on Green Trade Unveiled, Marking a New Phase of Systematic Advancement
Deep News  ·  11-15
China's First Specialized Policy on Green Trade Unveiled, Marking a New Phase of Systematic Advancement
Former GRI Director Lyu Jianzhong: ESG Standard Development Requires Balancing Three Key Aspects to Promote Shanghai’s Sustainable Development and Integration with Global Standards
Deep News  ·  10-17
Former GRI Director Lyu Jianzhong: ESG Standard Development Requires Balancing Three Key Aspects to Promote Shanghai’s Sustainable Development and Integration with Global Standards
US Imposes Additional Port Fees on Chinese Vessels: Shipping Companies Face Rising Costs as China Considers Countermeasures
Deep News  ·  10-09
US Imposes Additional Port Fees on Chinese Vessels: Shipping Companies Face Rising Costs as China Considers Countermeasures
Waterdrop Inc. Published 2024 ESG Report: Expanding Support to Vulnerable Groups, Providing Rural Medical Clinic Access to Over 500 Thousand Beneficiaries
prnewswire  ·  09-25
Waterdrop Inc. Published 2024 ESG Report: Expanding Support to Vulnerable Groups, Providing Rural Medical Clinic Access to Over 500 Thousand Beneficiaries
GRI Bio Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  09-22
GRI Bio Is Maintained at Buy by Ascendiant Capital
U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla
Reuters  ·  09-22
U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla
GRI Bio Inc : Ascendiant Capital Markets Raises Target Price to $35 From $34
THOMSON REUTERS  ·  09-22
GRI Bio Inc : Ascendiant Capital Markets Raises Target Price to $35 From $34
Former GRI Director Lv Jianzhong: Building an ESG Ecosystem of Risk Co-governance, Value Co-creation, Standard Co-construction, Platform Co-building, and Resource Sharing
Deep News  ·  09-19
Former GRI Director Lv Jianzhong: Building an ESG Ecosystem of Risk Co-governance, Value Co-creation, Standard Co-construction, Platform Co-building, and Resource Sharing
Worthington Enterprises Releases 2025 Corporate Citizenship and Sustainability Report
GlobeNewswire  ·  09-16
Worthington Enterprises Releases 2025 Corporate Citizenship and Sustainability Report
BUZZ-U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
Reuters  ·  09-12
BUZZ-U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
BRIEF-GRI Bio Reports 6-Week Interim Lung Function Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis
Reuters  ·  09-11
BRIEF-GRI Bio Reports 6-Week Interim Lung Function Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis
BUZZ-U.S. STOCKS ON THE MOVE -Apple, Enovix, Kroger
Reuters  ·  09-11
BUZZ-U.S. STOCKS ON THE MOVE -Apple, Enovix, Kroger
GRI Bio Shares up 123% Premarket After Co Reports Mid-Stage Trial Data for Lung Disease Drug
THOMSON REUTERS  ·  09-11
GRI Bio Shares up 123% Premarket After Co Reports Mid-Stage Trial Data for Lung Disease Drug
BUZZ-GRI Bio climbs on lung disease drug trial data
Reuters  ·  09-11
BUZZ-GRI Bio climbs on lung disease drug trial data
GRI Bio Inc - GRI-0621 Shows No Worsening of Fvc at 6 Weeks
THOMSON REUTERS  ·  09-11
GRI Bio Inc - GRI-0621 Shows No Worsening of Fvc at 6 Weeks
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“Ipf”)
THOMSON REUTERS  ·  09-11
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“Ipf”)
GRI Bio Inc - No Safety Concerns Observed by Idmc in GRI-0621 Study
THOMSON REUTERS  ·  09-11
GRI Bio Inc - No Safety Concerns Observed by Idmc in GRI-0621 Study

Introduction

Company Name.
GRI BIO INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.
Issue price:
--